Q1 Earnings Forecast for Quanterix Issued By Leerink Partnrs

Quanterix Co. (NASDAQ:QTRX) – Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Quanterix in a note issued to investors on Monday, March 17th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.69) per share for the quarter, down from their previous forecast of ($0.58). The consensus estimate for Quanterix’s current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($1.05) EPS.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The company had revenue of $35.16 million during the quarter, compared to the consensus estimate of $34.93 million.

Separately, Canaccord Genuity Group dropped their price objective on Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday.

Quanterix Stock Performance

Shares of NASDAQ:QTRX opened at $7.22 on Thursday. The firm’s 50 day simple moving average is $8.18 and its 200-day simple moving average is $10.84. Quanterix has a one year low of $6.30 and a one year high of $24.87. The firm has a market cap of $278.14 million, a PE ratio of -6.81 and a beta of 1.34.

Institutional Trading of Quanterix

A number of hedge funds have recently added to or reduced their stakes in QTRX. Ameriprise Financial Inc. raised its holdings in shares of Quanterix by 111.3% in the 4th quarter. Ameriprise Financial Inc. now owns 3,205,928 shares of the company’s stock valued at $34,079,000 after purchasing an additional 1,688,680 shares in the last quarter. William Blair Investment Management LLC bought a new position in Quanterix in the fourth quarter worth approximately $11,290,000. Portolan Capital Management LLC lifted its holdings in Quanterix by 31.4% during the third quarter. Portolan Capital Management LLC now owns 2,520,686 shares of the company’s stock worth $32,668,000 after buying an additional 602,656 shares during the period. Pier Capital LLC boosted its position in Quanterix by 32.8% during the 4th quarter. Pier Capital LLC now owns 679,680 shares of the company’s stock valued at $7,225,000 after acquiring an additional 167,882 shares in the last quarter. Finally, Williams Jones Wealth Management LLC. increased its holdings in shares of Quanterix by 39.9% in the 4th quarter. Williams Jones Wealth Management LLC. now owns 471,514 shares of the company’s stock valued at $5,012,000 after acquiring an additional 134,470 shares during the period. 86.48% of the stock is owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.